… The primary aim of this PMS was to confirm the safety of molnupiravir in Japanese patients
with infection caused by SARS-CoV-2 as early as possible after approval, and secondarily to …

… safety, efficacy, and virology data from the phase 2, dose-finding component of a trial evaluating
molnupiravir for … Molnupiravir maintains antiviral activity against SARS-CoV-2 variants in …

… molnupiravir and its active form against highly pathogenic SARS-CoV-2, the pathogen
responsible for COVID-19, and finding out the efficacy and safety of molnupiravir in clinical trials. …

… The molnupiravir group was associated with declines in SARS-CoV-2 RNA levels in …
The safety of molnupiravir was evaluated based on an analysis of a phase 3 double-blind …

… inhibit the replication of SARS-CoV-2. A significant advantage of molnupiravir is its favorable
… studies have shown the effectiveness and safety of molnupiravir as an antiviral therapy [23]. …

… of two phase 2 trials of molnupiravir. Second, the safety database is small and will
require … The UK summary report on molnupiravir recommends licensure for SARS-CoV-2–infected …

… safety of molnupiravir given within five days after the onset of signs or symptoms in unvaccinated
and non-hospitalized adults with mild or moderate SARS-CoV-2 … mg of molnupiravir as …

… evidence about the safety and efficacy of the molnupiravir administration in the … Molnupiravir
inhibits the RdRp enzyme of SARS-CoV-2, and causes several errors in the RNA virus …

… , molnupiravir (MOL), a new orally active RdRp inhibitor with a excellent pharmacokinetic
character, has demonstrated to have its ability to interfere SARS-COV-… and safety using MOL in …

… , a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob
… Optimal dose and safety of molnupiravir in patients with early SARS-CoV2: a Phase I, open-…